Medical Condition News

RSS

Ventus' PROVENT Sleep Apnea Therapy is runner-up at the The Wall Street Journal Technology Innovation Awards

Ventus Medical, a privately-held medical device company focused on improving the lives of patients with sleep-disordered breathing, today announced that the company's PROVENT(R) Sleep Apnea Therapy received the Runners-Up Award in The Wall Street Journal 2009 Technology Innovation Awards, Medical Devices category. The results were published in the September 14, 2009 edition of The Wall Street Journal.

22 Sep 2009

WHO emphasizes the importance of radon testing to prevent lung cancer

In simultaneous releases published around across the globe today, the World Health Organization (WHO) called for stronger action against indoor radon, the leading cause of lung cancer among U.S. and Canadian non-smokers.

22 Sep 2009

Patients with higher levels of vitamin D are less likely to die from skin cancer

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

22 Sep 2009

Gene variant shows a strong gender bias for cancer predisposition

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

22 Sep 2009

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Coenzyme Q10 to slow down the effects of Parkinson's disease?

Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States.

22 Sep 2009

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.

22 Sep 2009

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.

21 Sep 2009

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

New data on signalling proteins, called G proteins, may prove important in fighting diseases such as cardiovascular, neurodegenerative disorders, and cancer. For many decades scientists have puzzled on "How signalling proteins transport and organize in specific areas of the cell?" Researchers from Nano-Science Center and Department of Neuroscience and Pharmacology at the University of Copenhagen provide yet unrecognized clues to solve this mystery.

21 Sep 2009

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Three new HealthPartners Research Foundation studies will examine ways to prevent and treat childhood obesity and hypertension. One study will look at interventions to prevent obesity in children ages 5-9, another will focus on obesity prevention in children ages 2-5, while another will examine hypertension in children and adolescents, including the quality and cost of care.

21 Sep 2009

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.

21 Sep 2009

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The research suggests that GPs are still managing individual risk factors such as blood pressure and cholesterol in isolation of one another, and are not adopting recommendations to treat a patient's overall or absolute risk. Absolute risk management is based on the principle that the major risk factors for cardiovascular disease act together. By taking this approach treatment can be targeted to those most likely to benefit.

21 Sep 2009

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.

21 Sep 2009

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.

21 Sep 2009

New study reveals that large abdominal fat cells contribute to type 2 diabetes in women

Middle-aged women with large abdominal fat cells have a higher risk of developing type 2 diabetes later in life compared to women with smaller fat cells. Waist circumference divided by body height can also be used to determine which women are at risk. This is shown in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Sep 2009

Short-term psychodynamic psychotherapies for somatic symptom disorders show promise

In the current issue of Psychotherapy and Psychosomatics a meta-analysis indicates how short-term dynamic psychotherapy may be helpful in the setting of medical disease.

21 Sep 2009

Chronic viruses found living in prostate tumors

According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

21 Sep 2009

Medical Condition News

Ventus' PROVENT Sleep Apnea Therapy is runner-up at the The Wall Street Journal Technology Innovation Awards

WHO emphasizes the importance of radon testing to prevent lung cancer

Patients with higher levels of vitamin D are less likely to die from skin cancer

Gene variant shows a strong gender bias for cancer predisposition

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

Coenzyme Q10 to slow down the effects of Parkinson's disease?

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

New study reveals that large abdominal fat cells contribute to type 2 diabetes in women

MDC scientist receives 1 million euros for diabetic research

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Short-term psychodynamic psychotherapies for somatic symptom disorders show promise

Chronic viruses found living in prostate tumors

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News